BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8959418)

  • 1. Continuation rates among injectable contraceptive users.
    Westfall JM; Main DS; Barnard L
    Fam Plann Perspect; 1996; 28(6):275-7. PubMed ID: 8959418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An introductory clinical trial of three-monthly injectable contraceptive-depot medroxyprogesterone acetate].
    Shao Q; Jiang H; Fu W
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):36-9. PubMed ID: 11263172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuation of injectable contraceptives in Thailand.
    Narkavonnakit T; Bennett T; Balakrishnan TR
    Stud Fam Plann; 1982 Apr; 13(4):99-105. PubMed ID: 6216633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depo Now: preventing unintended pregnancies among adolescents and young adults.
    Rickert VI; Tiezzi L; Lipshutz J; León J; Vaughan RD; Westhoff C
    J Adolesc Health; 2007 Jan; 40(1):22-8. PubMed ID: 17185202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adolescent use of the monthly contraceptive injection.
    Tuchman LK; Huppert JS; Huang B; Slap GB
    J Pediatr Adolesc Gynecol; 2005 Aug; 18(4):255-60. PubMed ID: 16171729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of injectable contraceptive users in a low-income population in Texas.
    Sangi-Haghpeykar H; Poindexter AN; Moseley DC; Bateman L; Reid ED
    Fam Plann Perspect; 1995; 27(5):208-11, 225. PubMed ID: 9104608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability study of the two versus three monthly injectable contraceptives.
    Aly FA; El-genedi MM; Toppozada HK; El-abd M; Loutfi I
    Dirasat Sukkaniyah; 1984; 11(69):27-39. PubMed ID: 12179796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa.
    Beksinska ME; Rees HV
    Afr J Reprod Health; 2001 Dec; 5(3):84-8. PubMed ID: 12471932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
    Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA.
    Nelson AL; Katz T
    Contraception; 2007 Feb; 75(2):84-7. PubMed ID: 17241834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch?
    Thurman AR; Hammond N; Brown HE; Roddy ME
    J Pediatr Adolesc Gynecol; 2007 Apr; 20(2):61-5. PubMed ID: 17418388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
    Picardo C; Ferreri S
    Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depo-Provera: use of a long-acting progestin injectable contraceptive in Turkish women.
    Aktun H; Moroy P; Cakmak P; Yalcin HR; Mollamahmutoglu L; Danisman N
    Contraception; 2005 Jul; 72(1):24-7. PubMed ID: 15964288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
    Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
    Arch Pediatr Adolesc Med; 2005 Feb; 159(2):139-44. PubMed ID: 15699307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda.
    Cover J; Namagembe A; Tumusiime J; Nsangi D; Lim J; Nakiganda-Busiku D
    Contraception; 2018 Nov; 98(5):383-388. PubMed ID: 29654751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Community-based distribution of injectable contraceptives in an African setting: community trial in Madagascar].
    Brunie A; Hoke TH; Razafindravony B
    Sante; 2011; 21(1):21-6. PubMed ID: 21550921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
    Keder LM; Rulin MC; Gruss J
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.